ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them.…
ThinkstockAmgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes phase 3 RILOMET-1 and RILOMET-2 studies. The decision to discontinue was made based on…
Monday may have started out as a fairly quiet news day for most stock sectors on a shortened week, but don't tell that to the Ebola drug stocks.
24/7 Wall St. has identified five of the lowest performing health care stocks over the past month which need to catch up to peers.
As the Stifel health care conference continues, the firm posts four more stocks that it rates Buy that have incredible upside potential.
A new report from the biotech team at Stifel focuses on catalysts from companies that are presenting at the firm's annual health care conference.
Merrill Lynch released an analyst report for Orexigen Therapeutics that sees more than 50% upside for the company.
Providing care for a parent or loved one with Alzheimer's disease or other dementia costs $20,000 or more for 42% of Americans.
On Monday, Sunesis made an announcement that it would be making a presentation regarding its drug candidates vosaroxin and cytarabine.
Botox maker Allergan has entered a definitive agreement to be acquired by Actavis, despite higher offer from Valeant Pharmaceuticals.
Juno Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
Geron hasannounced that it entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize imetelstat.
ReWalk Robotics reported quarterly earnings Thursday morning for the first time since the company's initial public offering in mid-September.
A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand for the drugs they produce that treat hepatitis C.
Some Ebola-related stocks had been heavily shorted as they were considered by many investors as the next would-be stock bubble from a major news event.